Study points to potential new approach to treating neurodegenerative diseases like glaucoma and Alzheimer’s disease
Jul. 20, 2020—Researchers at Vanderbilt University Medical Center have shown for the first time that when one optic nerve in the eye is damaged, as in glaucoma, the opposite optic nerve comes to the rescue by sharing its metabolic energy.
Nov. 30, 2018—Tonia Rex and David Calkins were recently awarded National Eye Institute grants totaling $6.8 million over five years to develop new treatments for optic neuropathies and glaucoma, the leading cause of irreversible blindness.
Jun. 28, 2018—David Calkins, PhD, vice chair and director of Research at the Vanderbilt Eye Institute, has been granted one of the preeminent awards in vision research — the Research to Prevent Blindness (RPB) Stein Innovation Award.
Feb. 22, 2018—A team of researchers, led by David Calkins, PhD, vice chair and director of Research at the Vanderbilt Eye Institute, has made a breakthrough discovery in the field of glaucoma showing new hopes for treatments to preserve vision.
Oct. 5, 2017—The Vanderbilt Eye Institute (VEI) recently hosted the Southeastern Vision Conference to celebrate and share excellence in vision science.
Aug. 15, 2017—While agreeing that viewing a total solar eclipse is a chance of a lifetime, Vanderbilt Eye Institute Research Director David Calkins urges us to not look at the sun without special eclipse glasses. Catkins explains how certain spectrums of sunlight can damage your eyesight without you knowing it, until it is too late. Follow Vanderbilt...
Sep. 1, 2016—Researchers at Vanderbilt University Medical Center and Vanderbilt University have received a $1.9 million grant from the National Institutes of Health (NIH) to support research to restore vision through regeneration of the retina.
Jun. 25, 2015—The Vanderbilt Eye Institute recently received a grant for $115,000 from Research to Prevent Blindness, placing the total award amount for unrestricted grants from the organization at $860,000.
Dec. 16, 2014—Understanding how the protein TRPV1 helps neurons survive after glaucoma-related stressors could lead to new therapeutic strategies for glaucoma and other neurodegenerative conditions.
Oct. 2, 2014—Vanderbilt University has launched a regenerative visual neuroscience initiative to develop new ways of treating — and restoring sight to — people who have been blinded by glaucoma, macular degeneration, diabetic retinopathy and eye injuries.
Mar. 14, 2014—An ion channel protein called TRIPV1 helps retinal neurons survive the elevated eye pressure associated with glaucoma.
Sep. 19, 2013—Three years ago, a team of researchers led by David Calkins, Ph.D., vice chair and director of Research at the Vanderbilt Eye Institute, showed that the first sign of injury in glaucoma, the leading cause of blindness in the United States, occurs in the brain.